University of Lynchburg Doctoral Project Assignment Repository
Specialty
Primary Care
Abstract
Cardiovascular disease (CVD) remains the leading global cause of death, with obesity as a major driver of cardiometabolic dysfunction and increased cardiovascular risk. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established treatments for type 2 diabetes and obesity. Still, their role in reducing major adverse cardiovascular events (MACE) in non-diabetic adults is less well defined. This review evaluates current evidence on GLP-1 RA therapy in overweight and obese adults without diabetes. Findings from cardiovascular outcome trials and the SELECT study suggest that GLP-1 RAs may reduce MACE through both weight-dependent and weight-independent mechanisms, including reduced inflammation, improved endothelial function, and favorable effects on blood pressure and lipids. However, uncertainties remain regarding long-term safety, optimal treatment duration, and the persistence of benefit after discontinuation. Practical limitations—including gastrointestinal side effects, cost, and access barriers—also affect clinical use. Overall, GLP-1 RAs show promise for cardiovascular risk reduction in selected non-diabetic adults, but further research is needed.
Recommended Citation
Legendre C. Utilization of GLP-1 Receptor Agonists in Adults without Diabetes to Reduce Cardiovascular. University of Lynchburg Doctoral Project Assignment Repository. 2026; 8(1).
Restricted
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.